170 related articles for article (PubMed ID: 37922365)
1. Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments.
Rannikko JH; Bono P; Hynninen J; Hollmén M
Cancer Immunol Res; 2024 Jan; 12(1):48-59. PubMed ID: 37922365
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers.
Hollmén M; Maksimow M; Rannikko JH; Karvonen MK; Vainio M; Jalkanen S; Jalkanen M; Mandelin J
Mol Cancer Ther; 2022 Jul; 21(7):1207-1218. PubMed ID: 35500016
[TBL] [Abstract][Full Text] [Related]
3. Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko JH; Verlingue L; de Miguel M; Pasanen A; Robbrecht D; Skytta T; Iivanainen S; Shetty S; Ma YT; Graham DM; Arora SP; Jaakkola P; Yap C; Xiang Y; Mandelin J; Karvonen MK; Jalkanen J; Karaman S; Koivunen JP; Minchom A; Hollmén M; Bono P
Cell Rep Med; 2023 Dec; 4(12):101307. PubMed ID: 38056464
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of
Moisio O; Virta J; Yatkin E; Liljenbäck H; Palani S; Viitanen R; Miner MWG; Oikonen V; Tolvanen T; Vugts DJ; Taimen P; Li XG; Hollmén M; Jalkanen S; Roivainen A
J Nucl Med; 2023 Apr; 64(4):555-560. PubMed ID: 36302655
[TBL] [Abstract][Full Text] [Related]
5. Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes.
Ardighieri L; Missale F; Bugatti M; Gatta LB; Pezzali I; Monti M; Gottardi S; Zanotti L; Bignotti E; Ravaggi A; Tognon G; Odicino F; Calza S; Missolo-Koussou Y; Ries CH; Helft J; Vermi W
Front Immunol; 2021; 12():690201. PubMed ID: 34220848
[TBL] [Abstract][Full Text] [Related]
6. Tumor inherent interferons: Impact on immune reactivity and immunotherapy.
Brockwell NK; Parker BS
Cytokine; 2019 Jun; 118():42-47. PubMed ID: 29681426
[TBL] [Abstract][Full Text] [Related]
7. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Brempelis KJ; Cowan CM; Kreuser SA; Labadie KP; Prieskorn BM; Lieberman NAP; Ene CI; Moyes KW; Chinn H; DeGolier KR; Matsumoto LR; Daniel SK; Yokoyama JK; Davis AD; Hoglund VJ; Smythe KS; Balcaitis SD; Jensen MC; Ellenbogen RG; Campbell JS; Pierce RH; Holland EC; Pillarisetty VG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115946
[TBL] [Abstract][Full Text] [Related]
8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
9. Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.
Virtakoivu R; Rannikko JH; Viitala M; Vaura F; Takeda A; Lönnberg T; Koivunen J; Jaakkola P; Pasanen A; Shetty S; de Jonge MJA; Robbrecht D; Ma YT; Skyttä T; Minchom A; Jalkanen S; Karvonen MK; Mandelin J; Bono P; Hollmén M
Clin Cancer Res; 2021 Aug; 27(15):4205-4220. PubMed ID: 34078651
[TBL] [Abstract][Full Text] [Related]
10. Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients.
Adhikary T; Wortmann A; Finkernagel F; Lieber S; Nist A; Stiewe T; Wagner U; Müller-Brüsselbach S; Reinartz S; Müller R
BMC Genomics; 2017 Mar; 18(1):243. PubMed ID: 28327095
[TBL] [Abstract][Full Text] [Related]
11. The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.
Luo F; Li H; Ma W; Cao J; Chen Q; Lu F; Qiu M; Zhou P; Xia Z; Zeng K; Zhan J; Zhou T; Luo Q; Pan W; Zhang L; Lin C; Huang Y; Zhang L; Yang D; Zhao H
Cell Mol Immunol; 2024 Jan; 21(1):60-79. PubMed ID: 38062129
[TBL] [Abstract][Full Text] [Related]
12. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma.
Truxova I; Cibula D; Spisek R; Fucikova J
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822672
[TBL] [Abstract][Full Text] [Related]
14. Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.
Delitto D; Perez C; Han S; Gonzalo DH; Pham K; Knowlton AE; Graves CL; Behrns KE; Moldawer LL; Thomas RM; Liu C; George TJ; Trevino JG; Wallet SM; Hughes SJ
Cancer Immunol Immunother; 2015 Dec; 64(12):1553-63. PubMed ID: 26423423
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of adenosine on adaptive antitumor immunity and intervention strategies.
Wang L; Zhang W; Zhang J; Zheng M; Pan X; Guo H; Ding L
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Sep; 52(5):567-577. PubMed ID: 37916308
[TBL] [Abstract][Full Text] [Related]
16. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophage-targeted therapeutics in ovarian cancer.
An Y; Yang Q
Int J Cancer; 2021 Jul; 149(1):21-30. PubMed ID: 33231290
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
19. Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages.
Zhou J; Wang W; Li Q
J Exp Clin Cancer Res; 2021 Feb; 40(1):73. PubMed ID: 33596985
[TBL] [Abstract][Full Text] [Related]
20. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
